Use of effective part extract of
The present disclosure provides use of an effective part extract of Monochasma savatieri in preparation of a drug for treating an inflammatory disease or a tumor. In the present disclosure, an effective part of Monochasma savatieri is separated and purified by various separation and purification methods (including solvent extraction, macroporous resin column chromatography, MCI column separation, and Sephadex LH-20 gel column separation) separately, to obtain the effective part extract of Monochasma savatieri . The effective part extract of Monochasma savatieri is capable of significantly inhibiting secretion of TNF-α, and significantly inhibiting proliferation of breast cancer cells and lung cancer cells, thereby effectively treating the inflammatory disease or the tumor. The present disclosure provides a favorable theoretical basis for finding a drug that can effectively treat the inflammatory disease or the tumor from the Monochasma savatieri , which is of great significance to development of novel drugs.
1. A method for treating an inflammatory disease, comprising contacting inflamed tissue with a drug comprising an effective amount of an effective part of Monochasma savatieri extract, wherein the effective part of Monochasma savatieri extract consists of fraction B2-13, fraction B2-15, fraction B2-16, and fraction B2-16-15;
wherein fraction B2-13, fraction B2-15, fraction B2-16, and fraction B2-16-15 are obtained by the following process:
(1) pulverizing Monochasma savatieri to obtain Monochasma savatieri powder, mixing the Monochasma savatieri powder with water, conducting extraction 2 to 4 times by decoction for 20 min to 40 min each time, combining filtrates, and conducting vacuum concentration on a combined filtrate to obtain the Monochasma savatieri crude extract; wherein water is added in a volume to mass ratio of 4 L water/1 kg of Monochasma savatieri powder; and extraction by decoction is conducted at about 100° C.;
(2) separating the Monochasma savatieri crude extract by an HP-20 macroporous resin column chromatography, and conducting elution with 150 L to 250 L of water and 150 L to 250 L of 40% to 60% ethanol in sequence, to obtain fraction LRCW-A and fraction LRCW-B, respectively;
(3) separating the fraction LRCW-B by an MCI column chromatography, and conducting elution with 35 L to 45 L of water, 35 L to 45 L of 25% to 35% ethanol, 35 L to 45 L of 40% to 60% ethanol, and 35 L to 45 L of 80% to 95% ethanol, to obtain fraction LRCW-B1, fraction LRCW-B2, fraction LRCW-B3, and fraction LRCW-B4, respectively;
(4) separating the fraction LRCW-B2 by a cross-linked dextrin gel LH-20 gel column chromatography, and conducting gradient elution with absolute ethanol and water in a volume ratio of 1:0 to 0:1 as a mobile phase; and combining same fractions having a same R f value according to results of thin layer chromatography to obtain fraction B2-1, fraction B2-2, fraction B2-3, fraction B2-4, fraction B2-5, fraction B2-6, fraction B2-7, fraction B2-8, fraction B2-9, fraction B2-10, fraction B2-11, fraction B2-12, fraction B2-13, fraction B2-14, fraction B2-15, fraction B2-16, fraction B2-17, fraction B2-18, and fraction B2-19; and
(5) separating the fraction B2-16 by the cross-linked dextrin gel LH-20 gel column chromatography, and conducting gradient elution with absolute ethanol and water in a volume ratio of 1:0 to 0:1 as a mobile phase; and combining same fractions according to results of thin layer chromatography to obtain fraction B2-16-1, fraction B2-16-2, fraction B2-16-3, fraction B2-16-4, fraction B2-16-5, fraction B2-16-6, fraction B2-16-7, fraction B2-16-8, fraction B2-16-9, fraction B2-16-10, fraction B2-16-11, fraction B2-16-12, fraction B2-16-13, fraction B2-16-14, fraction B2-16-15, fraction B2-16-16, fraction B2-16-17, fraction B2-16-18, fraction B2-16-19, fraction B2-16-20, fraction B2-16-21, and fraction B2-16-22 wherein the inflammatory disease is caused by secretion of an inflammatory factor TNF-α.
2. The method according to claim 1 , wherein the inflammatory disease comprises sepsis, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, or psoriasis.
3. The method according to claim 1 , wherein the drug further comprises a pharmaceutically acceptable carrier or auxiliary material.